Bastiano Sanna - 14 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
14 Feb 2023
Net transactions value
-$655,161
Form type
4
Filing time
16 Feb 2023, 15:16:05 UTC
Previous filing
14 Feb 2023
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $571,152 -1,902 -3.1% $300.29 60,013 14 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $84,010 -279 -0.46% $301.11 59,734 14 Feb 2023 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92).
F4 Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22).